Samsung Bioepis and Regeneron Settle Patent Dispute Over Eylea Biosimilar
Feb 13, 2026
Samsung Bioepis and Regeneron reached a settlement allowing U.S. launch of Opuviz, an aflibercept biosimilar, in January 2027. The agreement resolves a patent dispute that began in late 2023.